Latest data updates for mRNA Revolution Tracker.https://watchboard.dev/en-ushttps://watchboard.dev/mrna-revolution/#digest-2026-06-02/https://watchboard.dev/mrna-revolution/#digest-2026-06-02/Skin cancer patients could soon benefit from a revolutionary mRNA-based vaccine shown to significantly slash recurrence risk, advancing the clinical case for personalized cancer immunotherapy beyond tTue, 02 Jun 2026 00:00:00 GMTbreakinghttps://watchboard.dev/mrna-revolution/#digest-2026-05-22/https://watchboard.dev/mrna-revolution/#digest-2026-05-22/The FDA announced a rare June 18 advisory committee hearing for Moderna's mRNA-1010 flu vaccine (PDUFA: August 5, 2026), sending MRNA stock down ~5.5% on May 21; if approved, mRNA-1010 would be the first mRNA seasonal flu vaccine in the US. BioNTech announced ASCO 2026 presentations on May 22 featuring pivotal pumitamig NSCLC Phase 2/3 data and six-year autogene cevumeran pancreatic cancer follow-up showing ~87.5% of immune responders still alive. A May 13 Nature Biotechnology study from MIT and Harvard described an mRNA-encoded IRF8+NIK adjuvant strategy that eradicated most tumors in mice and amplified T-cell responses 10–15×. Moderna's market cap updated to ~$11B reflecting the post-adcomm-announcement decline; BioNTech Q1 2026 financials confirmed €138M revenue and $19.6B cash.Fri, 22 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-05-21/https://watchboard.dev/mrna-revolution/#digest-2026-05-21/FDA Schedules June 18 Advisory Panel for Moderna mRNA Flu Vaccine; MRNA Stock Falls 5.5%.Thu, 21 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-05-13/https://watchboard.dev/mrna-revolution/#digest-2026-05-13/On May 13, 2026, MIT News reported a major preclinical advance in mRNA cancer vaccine technology developed by researchers from MIT, Harvard, and the University of Houston.Wed, 13 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-05-08/https://watchboard.dev/mrna-revolution/#digest-2026-05-08/A Nature Biotechnology paper from Mount Sinai (April 29) introduced precision mRNA cell-targeting technology that could boost cancer vaccine immunogenicity and open autoimmune applications. Moderna Q1 2026 revenue of $400M beat expectations; the EU approved next-gen COVID vaccine mNEXSPIKE (refrigerator storage) and the world's first flu+COVID combination mRNA vaccine mCOMBRIAX. BioNTech Q1 2026 results included a $1B buyback, five new pivotal oncology trials, and BNT116 showing 45% response rate in lung cancer Phase 1. The FDA announced a VRBPAC meeting for May 28 to select the 2026–2027 COVID vaccine strain, while reports emerged of the FDA blocking publication of completed vaccine safety studies — a significant policy development. Moderna also initiated a Phase 3 mRNA-4157 trial in Stage I lung cancer, expanding beyond melanoma.Fri, 08 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-05-05/https://watchboard.dev/mrna-revolution/#digest-2026-05-05/FDA Blocks Publication of COVID-19 and Shingles Vaccine Safety Studies.Tue, 05 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-05-04/https://watchboard.dev/mrna-revolution/#digest-2026-05-04/On May 4, 2026, BioNTech released Q1 2026 financial results showing revenue of €118.1M (vs.Mon, 04 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-05-01/https://watchboard.dev/mrna-revolution/#digest-2026-05-01/On May 1, 2026, Moderna reported Q1 2026 financial results, beating analyst consensus by approximately $164M: Q1 revenue reached $400M (vs.Fri, 01 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-04-29/https://watchboard.dev/mrna-revolution/#digest-2026-04-29/Nature Biotechnology: Mount Sinai Breakthrough Enables Precision Control of mRNA Vaccine Cell Targeting.Wed, 29 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-04-27/https://watchboard.dev/mrna-revolution/#digest-2026-04-27/FDA Announces VRBPAC Meeting to Select 2026–2027 COVID-19 Vaccine Strain.Mon, 27 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-04-24/https://watchboard.dev/mrna-revolution/#digest-2026-04-24/US researchers are testing a personalized mRNA-based vaccine designed to prevent tumor recurrence after initial cancer treatment, with early trial results suggesting the approach can prime the immune Fri, 24 Apr 2026 00:00:00 GMTbreakinghttps://watchboard.dev/mrna-revolution/#digest-2026-04-21/https://watchboard.dev/mrna-revolution/#digest-2026-04-21/AACR 2026 in San Diego delivered landmark mRNA oncology results this week. BNT122, the personalized mRNA pancreatic cancer vaccine from BioNTech/Genentech, showed ~50% of Phase 1 patients alive and cancer-free at 6 years — an extraordinary result for a disease with under 12% typical 5-year survival. Moderna's mRNA-4359 reported 83% overall response rate in first-line melanoma (Phase 1/2), while Abogen's novel mRNA-encoded T-cell engager ABO2203 achieved 100% complete response in the high-dose B-NHL cohort. The NCI announced a $200M cancer vaccine funding commitment at AACR, partially reversing 2025 pipeline cuts. Two new map points added (MSK, Genentech). KPIs updated to reflect V940 5-year survival data (49% death rate reduction). Ugur Sahin's role updated to reflect planned BioNTech departure.Tue, 21 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-04-20/https://watchboard.dev/mrna-revolution/#digest-2026-04-20/Dr. NCI Announces $200M Cancer Vaccine Funding at AACR as mRNA Pipeline Shows Resilience.Mon, 20 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-04-18/https://watchboard.dev/mrna-revolution/#digest-2026-04-18/At the ESCMID Global Congress in Munich (April 17–21, 2026), Moderna presented two late-breaking data sets relevant to mRNA vaccine revaccination in older adults.Sat, 18 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-04-17/https://watchboard.dev/mrna-revolution/#digest-2026-04-17/Moderna mRNA-4359 Shows 83% Response Rate in First-Line Melanoma at AACR 2026. Everest Medicines presented first-in-human Phase 1 data for EVM16, their proprietary personalized mRNA neoantigen cancer vaccine, at AACR 2026 in San Diego. ABO2203: mRNA-Encoded T-Cell Engager Achieves 100% Complete Response in High-Dose B-NHL Cohort.Fri, 17 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-04-16/https://watchboard.dev/mrna-revolution/#digest-2026-04-16/Storm Therapeutics Raises $56M Series C for mRNA Methylation Cancer Therapy.Thu, 16 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/mrna-revolution/#digest-2026-04-14/https://watchboard.dev/mrna-revolution/#digest-2026-04-14/Comprehensive seed backfill for the mRNA Revolution tracker covering the full platform timeline from the December 2020 COVID vaccine authorizations through 2026. Key milestones documented: FDA/EMA/WHO COVID mRNA vaccine approvals (2020–2022), bivalent booster authorizations, KEYNOTE-942 Phase 2 melanoma data (44% recurrence reduction), FDA Breakthrough Therapy Designation for mRNA-4157/V940, first non-COVID mRNA vaccine approvals (mResvia RSV, 2023), Nobel Prize to Karikó and Weissman, Japan's first saRNA approval (ARCT-154/Kostaive), Phase 3 cancer vaccine program launch, mRNA flu vaccine Phase 3, and advancing HIV/malaria/rare disease programs. Data populated across 6 sections: 8 KPIs, 30 timeline events (5 eras), 20 global map points, 15 contested claims, 12 key actors, and 8 economic indicators.Tue, 14 Apr 2026 00:00:00 GMTseed